INDO-NATIONAL LTD.

Indo National Ltd has announced the closure of its trading window for all designated persons, including promoters, directors, key managerial personnel, employees, insiders, connected persons, and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will remain shut from Wednesday, July 1, 2026, until 48 hours after the declaration of the company's unaudited first quarter results for the period ending June 30, 2026. During this period, these individuals are prohibited from trading in the company's securities. The trading window will reopen 48 hours after the announcement of the financial results.

Indo National Ltd has invested an additional ₹99.88 lakh in Medcuore Medical Solutions Private Ltd (MMSPL) by subscribing to equity shares. This investment represents an additional 1.68% of MMSPL's paid-up share capital on a fully diluted basis, increasing Indo National's aggregate shareholding to 59.16%. The acquisition does not fall under related party transactions. MMSPL's turnover for FY 25-26 was ₹1,45,60,000. The object of the acquisition is to facilitate business growth and generate revenue.

Indo National Ltd declared its audited financial results for the year ended March 31, 2026. The company's revenue from operations stood at ₹451 Cr. The Board of Directors recommended a dividend of ₹3.75 per share (75%) for the financial year ended March 31, 2026. The board also approved the re-appointment of the Cost Auditor and Internal Auditor.

Indo National Ltd's board recommended a dividend of ₹3.75 per share (75%) for the financial year ended March 31, 2026. The board also approved the audited standalone and consolidated financial statements for the same period. The meeting, held on May 15, 2026, also covered the re-appointment of the Cost Auditor and Internal Auditor. The financial results will be published in newspapers as per regulatory requirements.

Indo National Ltd's Board of Directors, at its meeting on May 15, 2026, approved the Audited Standalone and Consolidated Financial Statements for the quarter and year ended March 31, 2026. The statutory auditors, G Balu & Associates LLP, issued an unmodified opinion on these financial results. The Board also recommended a dividend of ₹3.75 per share, representing 75% for the financial year ended March 31, 2026. Additionally, the re-appointment of the Cost Auditor and Internal Auditor was approved.

Indo National Ltd's board approved audited standalone and consolidated financial results for the year ended March 31, 2026. The board recommended a dividend of ₹3.75 per share (75%) for FY26. Re-appointment of Cost and Internal Auditors was also approved. The meeting was held on May 15, 2026, commencing at 03:30 P.M and concluding at 05:00 P.M.

Indo National Ltd has invested an additional ₹80 lakh in Medcuore Medical Solutions Private Ltd (MMSPL), increasing its stake by 2.69% to a total of 57.48%. The acquisition, made through equity share subscription, aims to facilitate business growth and revenue generation for Indo National. The price per share was ₹9,187, based on a valuation report. MMSPL is involved in manufacturing, distribution, and services related to air monitoring systems and air purifiers. The investment is not a related party transaction.

Indo National Ltd has scheduled a Board of Directors meeting on May 15, 2026, to consider and approve the audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026. The board will also consider the recommendation of a dividend, if any. The company will publish the audited financial results in the newspapers after board approval. The trading window remains closed from April 1, 2026, until 48 hours after the declaration of results.

Indo National Ltd's Board has approved the acquisition of a 51% stake in Aidin Technologies Private Limited. The acquisition will be executed through the subscription of compulsorily convertible preference shares in two tranches. Aidin Technologies, incorporated in 2008, specializes in radio frequency power electronics, serving critical sectors like electronic warfare, defence communications, and satellite technology. This strategic move aims to establish Indo National in the high-growth Defence & Aerospace sector (B2B & B2G), diversifying its consumer-oriented business and leveraging the significant market opportunity in Defence Electronics, which is estimated at ₹25,000 Cr and growing at 12-14% CAGR. The acquisition is expected to boost revenue and profitability, creating a balanced business portfolio.

Indo National Ltd has announced the closure of the trading window for dealing in the securities of the company for all designated persons, including promoters, directors, key managerial personnel, employees, insiders, connected persons, and their immediate relatives. The closure is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended by SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018. The trading window will remain closed from Wednesday, 01st April 2026 till 48 hours after the announcement/declaration of the audited financial results of the company. During this period, they will not enter into any transactions involving securities of the Company. The Trading window will open 48 hours after the announcement/declaration of the audited financial results for the quarter and year ending 31st March 2026 to the stock exchanges. The date of the Board Meeting will be intimated separately.